FILARIASIS
LYMPHA TIC
WHO INFORMAL MEETING ON LYMPHATIC FILARIASIS
TRANSMISSION ASSESSMENT SURVEYS FOR REVIEW OF THE TRAINING
MODULES AND COORDINATION FOR COUNTRY SUPPORT
GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS
Preventive Chemotherapy and Transmission Control (PCT) Department of Control of Neglected Tropical Diseases (NTD) World Health Organization
20, Avenue Appia 1211 Geneva 27, Switzerland http://www.who,int/neglected_diseases/en
WHO HEADQUARTERS, GENEVA, SWITZERLAND 12–13 september 2012
S A
T
Global Programme to Eliminate Lymphatic Filariasis
Report of an informal meeting on transmission assessment surveys for
review of the training modules and coordination for country support
WHO headquarters, Geneva, 12–13 September 2012
© World Health Organization 2013
All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications—whether for sale or for noncommercial distribution—should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in this publication.
WHO/HTM/NTD/PCT/2013.6
Contents
Background ... 1
Objectives of the meeting... 1
Introduction and welcoming remarks... 2
Key discussion points ... 3
Recommendations ... 4
Next steps ... 6
Annex 1. List of participants... 7
Annex 2. Agenda ... 9
Annex 3. GPELF (provisional) projected number of target population in 2012–2020 ... 11
Annex 4. Projected needs of ICT cards (minimum requirement)... 13
Background
In 2011, the World Health Organization’s Global Programme to Eliminate Lymphatic Filariasis published Monitoring and epidemiological assessment of mass drug administration: a manual for national elimination programmes, which describes a new methodology for conducting Transmission Assessment Surveys (TAS).1 TAS are conducted to determine whether a series of mass drug administration (MDA) has successfully reduced prevalence of the infection below the threshold where transmission is likely no longer sustainable even in the absence of MDA, and thus to stop MDA. In order to support national programmes to build capacity to plan and implement TAS according to WHO’s new guidance, a 3-day training course comprising a series of modules was drafted. The first informal meeting on TAS was held at WHO’s headquarters in Geneva, Switzerland in February 2012 with WHO regional offices and key partners to share the training modules and discuss practical arrangements for the regional training workshops.
Regional workshops were organized accordingly during 2012 in Manila and Nadi by the WHO Regional Office for the Western Pacific, in Pondicherry by the WHO Regional Office for South- East Asia and in Cairo by the WHO Regional Office for the Eastern Mediterranean.
In anticipation of progressively rolling out training and implementing TAS in endemic countries, WHO organized an informal meeting in Geneva on 12–13 September 2012 to review the
outcomes of the regional training workshops held during 2012 in the Western Pacific, South-East Asia and Eastern Mediterranean regional offices and the training modules used; to clarify the issues identified during the workshops; and to discuss the collaboration and coordination plan with key partners to support countries for training and implementation of TAS in the future.
Objectives of the meeting
The objectives of the informal meeting were:
To clarify the framework of TAS including training and to translate the TAS guidelines into operation;
To discuss the scope, style and contents of WHO’s TAS training material and the timeline for its finalization; and
1 Monitoring and epidemiological assessment of mass drug administration: a manual for national elimination programmes. Geneva, World Health Organization, 2011 (WHO/HTM/NTD/PCT/2011.4).
To develop a roadmap and define responsibilities for future collaboration and coordination with key partners for country support.
Expected outcomes included:
Clear and operational framework of TAS and training;
Scope, contents and style of WHO TAS training material and the timeline its finalization;
and
A roadmap for future collaboration and coordination with key partners for country support.
The meeting was attended by 17 participants from partner organizations, WHO headquarters and WHO regional offices (Annex 1). The majority of the participants served as facilitators in at least one of the regional TAS training workshops and/or had participated in TAS
implementation. Dr Patrick Lammie was elected Chair of the meeting and Katie Zoerhoff was elected Rapporteur. The provisional agenda is attached as Annex 2.
Introduction and welcoming remarks
Dr Savioli welcomed the participants to the meeting and described how TAS training fits within the larger context of overcoming neglected tropical diseases. Dr Ichimori outlined the
background, objectives and expected outcomes of the meeting, and emphasized that the next steps are to translate the guidelines into action through TAS training and implementation. Dr Yajima reported the progress of the Global Programme to Eliminate Lymphatic Filariasis worldwide and the regional TAS workshops, highlighting the multiple players involved in TAS, including the Global Programme and national programmes to eliminate lymphatic filariasis, and those involved in implementing surveys in implementation units or evaluation units. These players have various roles in planning, implementing, reporting, reviewing and endorsing elimination activities. TAS workshop facilitators summarized the WHO regional TAS training workshops using the draft training materials and the needs for regional TAS training. Dr Yajima proposed a framework for consideration in developing the TAS training material. Participants reviewed the content in each of the 11 training modules.
On the second day, the participants determined the structure of the TAS training curriculum.
Partners shared their previous and potential future support for capacity-building and implementation; an inventory of support for implementation at the country level showed
substantial commitment from donors and partners. However, there remain a number of countries with gaps that are not yet met. A draft reporting form for determining TAS eligibility, recording the survey design, and reporting results was presented and discussed. Participants then discussed
the availability of immunochromatographic tests (ICT) for TAS planning and implementation.
After concluding discussions, the Chair thanked WHO and meeting participants and closed the meeting.
Key discussion points
Significance of TAS for the Global Programme. Participants recognized the significance of TAS as a tool for measuring progress towards elimination. They agreed that TAS should be viewed by all stakeholders as a standard component of monitoring and evaluation for the elimination programme; it is important that TAS be conducted at the appropriate time and with high quality. While the guidelines provide general guidance on TAS eligibility and survey design, country-specific assistance may be required to recommend when and how TAS is implemented.
Importance of capacity-building for TAS. Given the programmatic importance of properly implemented TAS, participants agreed the need for strengthening national programmes’ capacity to plan and implement TAS. Participants noted the value of refresher training, since TAS
guidelines may be refined through country experience and because of potential turnover of national programme staff.
In addition to the staff who are routinely involved in national elimination programme activities, participants recognized the need to increase the capacity of national decision-makers and the media to understand TAS implementation and stopping MDA in the context of the elimination programme.
It was agreed that the materials developed to date are a strong foundation for building national programmes’ capacity, as participants in the regional workshops achieved the workshop
objective to develop skills to plan and implement TAS. With slight revisions to the content, and the addition of a Learner’s Guide, a Facilitator’s Guide and a Position Statement, the training materials can be provided to the WHO Working Group on Capacity Building for rolling out workshops according to regional- and country-specific needs.
Need for coordination across stakeholders around TAS. Participants recognized the multiple stakeholders involved in TAS and discussed the various roles required to ensure effective TAS implementation. However, at this time, there is limited communication between national
programmes, the Global Programme, Regional Programme Review Groups, and donors/partners around planning TAS and sharing results. There is a need for coordination among stakeholders to ensure that TAS is implemented at an appropriate time and with high quality, and to share results so that suitable next steps can be identified and global progress assessed.
Value of proper data management. Accurate data are paramount to determine TAS eligibility for each evaluation unit, determine the survey design, make decisions based on the results of the TAS, and develop and implement post-intervention surveillance to detect recrudescence of transmission. Participants recognized the value of standard forms to help determine TAS eligibility, record the survey design and share results. As much of the data to determine TAS eligibility are already collected in WHO’s Joint Reporting Form, it would be beneficial for the forms to converge where possible, recognizing there might be a need for countries to report additional data in the case of earlier incomplete reporting.
Importance of ICT availability. The group reviewed the status of country progress and WHO’s projection need for ICT cards (Annexes 3 and 4). Approximately 3 million ICT cards will be needed per year for the next 5–6 years for TAS implementation. Concern was expressed over the availability of ICT cards for planning and implementing TAS, as ICT cards are vital for TAS implementation with the current guidelines and diagnostic tools available. Funding has been made available from the Bill & Melinda Gates Foundation to the test manufacturer to develop a less expensive and more robust ICT test; however, the schedule for introducing this test is not clear.
Recommendations
Meeting participants agreed the following recommendations:
TAS training curriculum
- Future TAS trainings should use the TAS training curriculum, once finalized, adapted to each region’s context. The curriculum will be available as a Learner’s Guide, a Facilitator’s Guide and a WHO Position Statement. The Position Statement should be developed to inform decision-makers and the media about TAS and stopping MDA for LF.
- Instructional videos demonstrating how to use ICT and Brugia Rapid diagnostic tests should be developed and included in training materials. Survey Sample Builder should also be included in training materials.
- Regional refresher trainings can be provided for national programme staff approximately every 2 years, with the possibility of integrating other trainings as relevant material become available. Country trainings can be coordinated through partners.
- National programmes should take responsibility for organizing and training their teams. The facilitator training tools can emphasize which modules and skills
should be focused for each group.
Standard forms should be used for making decisions about TAS eligibility and reporting in order to (i) ensure TAS implementation with appropriate timing, (ii) empower
Regional Programme Review Groups (RPRGs) with the information necessary to review and endorse TAS plans, and (iii) facilitate communication among national programmes, RPRGs, WHO’s regional offices and headquarters, and other partners. These forms should be part of WHO’s reporting package.
There is an urgent need for the new ICT test to be available for use by national
programmes. WHO and partners should develop a transition plan for rolling out the new diagnostic test with high quality, including side-by-side testing of old and new versions of ICT, making operational recommendations to programmes about the use of the test and updating the TAS training material. The manufacturer is urged to maintain adequate supply of the old version of the test until the Global Programme is able to roll out the new version. Once the new ICT test is available, partners should support training of national programme staff.
TAS coordination
- Donors are encouraged to work with WHO to maintain updated ICT forecasting to facilitate coordination with the manufacturer.
- WHO and the Global Alliance to Eliminate Lymphatic Filariais should convene a meeting of donors to identify mechanisms for high-priority countries not already receiving support for national NTD programmes, particularly TAS
implementation.
- The key TAS implementation partners who participated in the meeting (but not limited to) will serve as a TAS Coordination Group and should support WHO in capturing TAS results, to provide an accurate measure of Global Programme.
Role of Regional Programme Review Groups
- Technical review by RPRG before and after TAS, as part of programmatic oversight role, could facilitate communication linkage between countries and WHO.
- RPRG recommendations around TAS eligibility could be made throughout the year on a virtual basis.
- RPRG members should receive technical training on TAS in order to ensure that systematic approaches to determine TAS eligibility and interpretation of results are applied across countries and regions.
Access to technical documents by national programmes is a critical issue. Partners should update their web sites to make documents available. The WHO Working Group on Capacity Building will be well-positioned to coordinate with headquarters, regional offices and countries to ensure dissemination.
The PCT databank and the Weekly Epidemiological Record were recognized as key sources of data for monitoring country progress and forecasting; their contents should be further enhanced to include annually updated forecasts to enhance use by and feedback to key stakeholders.
Next steps
Submit final draft of the WHO TAS training material and WHO position statement for WHO editing (end of November 2012).
Present WHO TAS training material and WHO position statement to STAG M&E WG (February 2013).
Publish web version of WHO TAS training material and WHO position statement for RPRG meetings (for April–May 2013).
·
Annex 1. List of participants
PARTICIPANTS
Mr Brian CHU
Research Project Manager, The Task Force for Global Health 325 Swanton Way, Decatur, GA, USA
Tel: +1 (404) 592 1427; e-mail: bchu@taskforce.org Dr Patricia GRAVES
School of Public Health, Tropical Medicine and , Rehabilitation Sciences, James Cook University PO Box 6811, Cairns, QLD 4870, Australia
Tel: + +61 424 096 571; e-mail: Pgraves.work@gmail.com Professor John GYAPONG
Pro-Vice Chancellor, Research Innovation and Development, University of Ghana P.O. Box LG571, Accra, Legon, Ghana
Tel: +233 302 213 820; Mobile: +233 244 265081; e-mail: jgyapong@ug.edu.gh Dr Louise KELLY HOPE
Project Manager, Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Pembroke Place, Liverpool, L3 5QA, UK
Tel: 0044 151 705 3336; e-mail: lkhope@liv.ac.uk / l.kelly-hope@liv.ac.uk Dr Kaliannagounder KRISHNAMOORTHY1
Deputy Director (Sr. Grade), Vector Control Research Center Pondicherry – 605 006, India
Tel: +91-413-2279158; e-mail: kkrish_3@yahoo.com Dr Patrick LAMMIE
Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention Mail Stop D-65, 1600 Clifton Rd., Atlanta, GA 30329, USA
Tel: +1 404 718 4135; e-mail: pjl1@cdc.gov Dr Eric OTTESEN1
Director, Lymphatic Filariasis Support Center, The Task Force for Global Health 325 Swanton Way, Decatur, GA 30030, USA
Tel: +1 404 687 5602; Fax: +1 404 371 1138; e-mail: EOttesen@taskforce.org Dr Reda RAMZY
National Nutrition Institute, General Organization for Teaching Hospitals & Institutes 16 Kasr El Aini St., Cairo 11556, Egypt
Tel: +202 3338 8424; Fax: +202 3338 8424; e-mail: reda_m@masrawy.com Dr Maria REBOLLO
1 Invited but unable to attend.
Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine Pembroke Place, Liverpool L3 5QA, UK
Tel: +44 7527520139; Mb: +44 7889720324; e-mail: maria.rebollo@liv.ac.uk Ms Angela WEAVER1
U.S. Agency for International Development
Ronald Reagan Building,Washington, DC 2052–1000, USA
Tel: +1 202-712-5603; Fax: +1 202.216.3702; e-mail: aweaver@usaid.gov Ms Kimberly WON
Health Scientist, CDC/CGH/DPDM, Centers for Disease Control and Prevention 1600 Clifton Road, MS D-65, Atlanta, GA 30329, USA
Tel: +1 404 718-4137; e-mail kwon@cdc.gov Ms Katie ZOERHOFF
Monitoring & Evaluation Specialist
NTD Control Program/ENVISION, RTI International
701 13th St NW, Ste 750, Washington, DC 20005–2207, USA Tel: +1 202.974.7866; e-mail: Kzoerhoff@rti.org
WHO SECRETARIAT
Dr Dirk ENGELS, Coordinator, NTD/PCT Tel: +41 22 791 3824 CH - 1211 Geneva 27, SWITZERLAND e-mail: engelsd@who.int Dr Kazuyo ICHIMORI, NTD/PCT Tel: +41 22 791 27 67 CH - 1211 Geneva 27, SWITZERLAND e-mail: ichimorik@who.int Dr Aya YAJIMA, NTD/PCT Tel: +41 22 791 3554 CH-1211 Geneva 27, SWITZERLAND e-mail: yajimaa@who.int Dr Albis GABRIELLI, NTD/PCT Tel: +41 22 791 1876 CH-1211 Geneva 27, SWITZERLAND e-mail: gabriellia@who.int Dr Antonio MONTRESOR, NTD/PCT Tel: +41 22 791 3322 CH-1211 Geneva 27, SWITZERLAND e-mail: montresora@who.int Dr Pamela MBABAZI, NTD/PCT Tel: +41 22 791 4855 CH-1211 Geneve 27, SWITZERLAND e-mail: mbabazip@who.int Dr Francesco RIO, NTD/CCB Tel: +41 22 791 5544 CH-1211 Geneva 27, SWITZERLAND e-mail: riof@who.int EMRO
Dr Hany ZIADY Mb: +201 006011517
Cairo, EGYPT e-mail: ziadyh@emro.who.int
1 Invited but unable to attend.
Annex 2. Agenda
PROVISIONAL AGENDA
Day 1: Wednesday, 12 September 2012, Salle M. 105
Time Subject Facilitator
09:00 – 9:15 hrs
1. Opening session
- Welcoming remarks
- Introduction of the participants
- Nomination of the chair and rapporteur
Dirk Engels/
Kazuyo Ichimori
09:15 – 09:30 hrs
2. Background
- Objectives of the meeting - Expected outcome
- Agenda
Kazuyo Ichimori
09:30 – 09:50 hrs 3. Global progress of TAS capacity building Aya Yajima 09:50 – 10:30 hrs
4. WHO Regional TAS Training Workshops - WPRO
- SEARO
Kimberly Y Won K. Krishnamoorthy 10:30 – 11:00 hrs Coffee break
11:00 – 12:30 hrs
4. WHO Regional TAS Training Workshops - EMRO
- AFRO - AMRO
- Summary and discussion
Reda Ramzy John Gyapong Pat Lammie Chair 12:30 – 14:00 hrs Lunch break
5. TAS Framework
- Key questions Aya Yajima
14:00 – 15:30 hrs
- Discussion Chair
15:30 – 16:00 hrs Coffee break
16:00 – 17:00 hrs 5. TAS Framework – Discussion (continued) Chair 17:00 – 17:30 hrs 5. Conclusion of TAS Framework Chair 17:30 – 19:00 hrs Reception – Main Cafeteria
Day 2: Thursday, 13 September 2012, Salle C.102
Time Subject Facilitator
09:00 – 10:30 hrs
6. TAS training material: Contents - Key questions
- Discussion
Aya Yajima Chair 10:30 – 11:00 hrs Coffee break
11:00 – 12:00 hrs 6. Contents – Discussion (continued) Chair
12:00 – 12:30 hrs 6. Conclusion of Contents and next steps Chair 12:30 – 14:00 hrs Lunch break
7. TAS implementation 7.1. Global progress
Aya Yajima 7.2. Country support
14:00 – 15:30 hrs o USAID o CDC o RTI o Task Force o CNTD
Angela Weaver Kimberly Y Won Katie Zoerhoff Brian Chu Maria Rebollo 15:30 – 16:00 hrs Coffee break
16:00 – 17:00 hrs 7.3. ICT issue Chair
17:00 – 17:30 hrs 8. Conclusion and recommendations Chair 17:30 hrs Closing
Annex 3. GPELF (provisional) projected number of target population in 2012–2020
GPELF (Provisional) projected number of target population in 2012‐2020 Updated 041012
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
AFR Burundi
AFR Cape Verde AFR Mauritius
AFR Rwanda
AFR Seychelles AMR Costa Rica
AMR Surinam
AMR Trinidad & Tobago WPR Solomon Islands
AFR Comoros 0.37 0.40 0.03 0.35 0.53 0.54 0.55 0.56 0.57
AFR Gambia 0.20 0.40 0.60 1.37 1.40 1.00 0.60 0.40
AFR Kenya 1.15 1.21 1.09 1.26 3.11 3.19 2.27 1.52 1.52
AFR Madagascar 0.59 2.13 2.91 4.89 5.05 6.87 19.09 19.59 11.41 11.41 8.95 AFR
Sao Tome and
Principe 0.42 0.27 0.41 0.44 0.44
AFR Zambia 1.10 2.20 4.40 9.69 9.94 7.68 6.58
AFR Zimbabwe 0.75 1.25 3.00 6.47 6.56 5.25
AFR Angola 6.00 10.00 14.23 14.62 15.02 6.10 2.10
AFR Benin 0.68 1.13 1.52 1.46 1.49 0.90 0.91 0.95 0.53 5.44 4.20 4.20 4.20 AFR Burkina Faso 5.50 6.24 10.49 11.13 11.61 12.04 12.33 12.83
AFR Côte d'Ivoire 0.91 2.46 14.00 14.00 14.00 14.00 13.00
AFR Cameroon 1.17 0.62 3.68 7.94 10.00 10.31 10.31 10.31 3.31 3.31
AFR Central African
Republic 1.00 2.00 3.69 3.75 3.82 2.30 1.30
AFR Chad 3.00 5.00 8.52 8.75 8.99 4.27 2.27
AFR Congo 1.00 1.00 2.97 3.03 3.10 1.60 1.60
AFR Democratic
Republic of C ongo 20.00 35.00 49.14 49.14 49.14 29.00 15.00
AFR Equatorial Guinea 0.20 0.20 0.49 0.50 0.51 0.20 0.20
AFR Eritrea 1.00 2.00 4.27 4.39 4.52 2.58 1.58
AFR Ethiopia 0.08 0.07 0.08 10.00 20.00 32.38 29.00 29.00 19.00 9.00
AFR Gabon 1.00 1.00 1.44 1.46 1.49 0.29 0.29
AFR Ghana 2.68 3.97 5.14 6.03 5.93 7.23 7.20 7.49 7.76
AFR Guinea 2.00 4.00 6.92 7.11 7.30 4.07 2.07
AFR Guinea-Bissau 1.00 1.00 1.50 1.54 1.57 0.31 0.31
AFR Liberia 1.37 2.74 3.95 4.08 2.23 2.23 0.86
AFR Malawi 2.70 10.81 10.80 11.26 13.81 9.53
AFR Mali 0.48 2.32 4.53 5.07 9.73 10.05 11.93 7.70 5.11
AFR Mozambique 1.61 3.74 8.50 17.87 18.26 12.26 8.00
AFR Niger 2.22 3.85 6.52 7.80 7.39 8.42 4.95 2.51
AFR Nigeria 3.11 3.24 3.40 3.34 3.41 3.88 4.75 10.08 18.59 32.28 54.48 76.69 99.18 101.40 103.67 35.70 25.70 15.70
AFR Senegal 0.47 0.45 0.41 5.45 4.70 4.70 4.70
AFR Sierra Leone 1.18 3.18 3.48 4.76 5.07 6.43 6.59 0.82 0.82 AFR Togo 0.86 0.89 0.93 0.95 0.97 0.94 0.33
AFR Uganda 1.16 3.48 4.92 6.45 9.18 8.77 15.19 15.69 16.21 16.75 8.00 AFR United Republic of
Tanzania 2.34 4.23 0.93 6.07 6.39 3.14 4.40 4.47 10.91 39.64 40.82 42.04 43.30 21.65 AMR Dominican Republic 0.25 0.40 0.04 0.19 0.10 0.03 0.03 0.03 0.03 0.03
AMR Guyana 0.43 0.40 0.13 0.04 0.03 0.57 0.69 0.69 0.69 0.69 0.12
AMR Haiti 0.58 1.07 1.26 0.77 2.55 3.06 3.95 8.79 9.62 9.62 9.77 6.32 4.82 1.82 AMR Brazil 0.04 0.06 0.08 0.11 0.19 0.18 0.15 0.15 0.22 0.11 0.22
EMR Egypt 2.55 2.58 0.69 0.44 0.28 0.48 0.50 0.50 0.53
EMR Sudan 6.00 6.00 8.00 8.00 8.00 6.00 6.00 4.00 4.00
EMR Yemen 0.08 0.14 0.09 0.09 0.03 0.03 0.03 0.04
SEAR Bangladesh 6.17 16.18 17.23 21.97 25.15 14.33 31.85 33.57 22.14 50.00 78.00 79.04 41.00 34.00 SEAR India 48.76 276.79 346.44 302.67 421.25 374.34 336.57 292.84 342.41 605.39 613.53 150.00 100.00
SEAR Indonesia 0.64 1.25 2.90 5.33 8.41 12.31 19.16 18.46 21.84 58.60 97.00 136.14 68.40 63.00 46.10 30.00 19.40 17.50
SEAR Maldives 0.00 0.00 0.00 0.00
SEAR Myanmar 7.67 15.84 10.65 18.40 15.79 9.00 15.33 41.89 42.70 42.70 SEAR Nepal 0.41 1.45 2.60 1.73 8.78 8.79 8.28 11.51 12.28 23.00 26.34 26.80 SEAR Sri Lanka 8.58 8.58 8.57 8.76
SEAR Thailand 0.12 0.13 0.14 0.11 0.06 0.08 0.08 0.08 0.08
SEAR Timor-Leste 0.29 0.32 0.27 1.08 1.12 1.16 1.20 1.24
WPR American Samoa 0.04 0.04 0.04 0.04
WPR Brunei Darussalam 0.02 0.02
WPR Cambodia 0.31 0.34 0.39 0.41 0.43
WPR Cook Islands 0.01 0.01 0.01
WPR Fiji 0.48 0.54 0.53 0.48 0.33 0.47 0.28 0.46 0.89 0.40 WPR French Polynesia 0.22 0.23 0.26 0.27 0.04 0.18 0.23 0.27
Country No. people treated in 2003-2011 (x million) Projected No. target population in 2012-2020 (x million) Region
WPR
Lao People's Democratic
Republic 0.01 0.01 0.09 0.07 0.13 0.13 0.13
WPR Malaysia 0.26 0.78 0.83 0.83 0.96 0.44 0.61 WPR Marshall Islands 0.00 0.00
WPR
Micronesia (Federated States
of) 0.00 0.00 0.00
WPR New C aledonia
WPR Niue 0.00 0.00
WPR Palau
WPR Papua New Guinea 0.20 0.59 0.13 0.07 2.46 5.86 5.99 6.13 6.27 6.41 WPR Philippines 9.09 8.80 9.88 10.17 13.63 14.58 15.88 15.18 19.46 32.83 3.00 3.00
WPR Samoa 0.14 0.14 0.16 0.19 0.19
WPR Tonga 0.09 0.08 0.08 0.00
WPR Tuvalu 0.01 0.01 0.01 0.00 0.00
WPR Vanuatu 0.16 0.16
WPR Viet Nam 0.11 0.59 0.57 0.60 0.59 WPR Wallis and Futuna 0.01 0.01 0.01 0.01 0.01 SUMMARY
16.70 21.25 28.16 33.46 46.38 56.98 69.13 82.39 112.83 212.80 240.84 280.91 329.92 301.32 236.63 144.98 74.82 40.35 1.26 1.51 1.75 0.27 0.98 2.74 3.36 4.14 8.97 10.45 10.46 10.71 7.04 5.54 1.94
72.35 320.21 378.17 351.53 482.32 425.63 395.93 365.46 414.08 779.97 858.69 435.84 210.60 98.24 46.10 30.00 19.40 17.50 2.63 2.72 0.78 0.54 0.31 0.51 0.03 0.50 0.53 6.53 6.00 8.00 8.00 8.00 6.00 6.00 4.00 4.00
10.67 10.54 12.75 13.51 15.48 16.45 16.77 15.90 20.76 37.38 9.59 9.13 6.13 6.27 6.41
103.60 356.22 421.61 399.31 545.48 502.31 485.23 468.39 557.17 1,047.13 1,125.57 744.59 561.69 419.37 297.08 180.98 98.22 61.85 SEAR
• Number of people treated in 2003‐2011 is based on the WHO PCT Databank and WER.
• Number of target population in 2012‐2020 was projected in 2011 in consultation with Regional Offices, based on country/regional plans, the targets set in the GPELF Strategic Plan (WHO 2010) and the assumption that an IU moves to post‐MDA surveillance phase after 5 rounds of effective MDA (i.e. >65% coverage).
• The projection will be updated in consultation with Regional Officers on annual basis prior to publication in WER.
EUR WPR GLOBAL AFR AMR EMR
Annex 4. Projected needs of ICT cards (minimum requirement)
Region 2013 2014 2015 2016 2017 2018
AFR 176,000 102,000 118,000 84,000 64,000 32,000
AMR 16,000 16,000 14,000 12,000 10,000 6,000
EMR 8,000 36,000 ‐ ‐ ‐ ‐
SEAR 1,374,000 520,000 474,000 226,000 204,000 54,000
MEK 52,000 24,000 22,000 18,000 12,000 12,000
PAC 18,000 20,000 10,000 18,000 10,000 14,000
Global 1,644,000 718,000 638,000 358,000 300,000 118,000
Assumptions:
i) IUs are combined (or divided) to make up max 2 million population per EU ii) 2000 ICT cards are required per EU
iii) Estimation is based only on countries currently implementing MDA. Countries that have not started MDA as of 2012 are expected to start requiring ICT cards after 2018, at earliest
Preventive Chemotherapy and Transmission Control (PCT) Department of Control of Neglected Tropical Diseases (NTD) World Health Organization
